Selective oestrogen receptor modulation: Molecular pharmacology for the millennium (Reprinted from Eur J Cancer, vol 35, pg 1974-1985, 1999)

被引：50

作者：

Levenson, AS ^{[1
]}

Jordan, VC ^{[1
]}

机构：

[1] Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctrt, Chicago, IL 60611 USA

来源：

EUROPEAN JOURNAL OF CANCER | 1999年 / 35卷 / 14期

关键词：

tamoxifen; raloxifene; breast cancer; prevention;

D O I：

10.1016/S0959-8049(99)00297-X

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Knowledge of the mechanism of action and pharmacology of tamoxifen and raloxifene, for the prevention of breast cancer and osteoporosis respectively, has opened the door for the discovery of multifunctional medicines. There is now the potential to prevent osteoporosis, coronary heart disease, breast and endometrial cancer in postmenopausal women with elevated risk factors. (C) 1999 Elsevier Science Ltd. All rights reserved.

引用

页码：1974 / 1985

页数：12

共 134 条

[1] STIMULATION OF ESTROGEN RECEPTOR-MEDIATED TRANSCRIPTION AND ALTERATION IN THE PHOSPHORYLATION STATE OF THE RAT UTERINE ESTROGEN-RECEPTOR BY ESTROGEN, CYCLIC ADENOSINE-MONOPHOSPHATE, AND INSULIN-LIKE GROWTH FACTOR-I [J].

ARONICA, SM ;

KATZENELLENBOGEN, BS .

MOLECULAR ENDOCRINOLOGY, 1993, 7 (06) :743-752

[2] A realistic clinical perspective of tamoxifen and endometrial carcinogenesis [J].

Assikis, VJ ;

Neven, P ;

Jordan, VC ;

Vergote, I .

EUROPEAN JOURNAL OF CANCER, 1996, 32A (09) :1464-1476

[3]

BAUMLER E, 1984, P EHRLICH SCI LIFE

[4] Differential ligand-dependent interactions between the AF-2 activating domain of nuclear receptors and the putative transcriptional intermediary factors mSUG1 and TIF1 [J].

Baur, EV ;

Zechel, C ;

Heery, D ;

Heine, MJS ;

Garnier, JM ;

Vivat, V ;

LeDouarin, B ;

Gronemeyer, H ;

Chambon, P ;

Losson, R .

EMBO JOURNAL, 1996, 15 (01) :110-124

[5] Interaction of steroid hormone receptors with the transcription initiation complex [J].

Beato, M ;

SanchezPacheco, A .

ENDOCRINE REVIEWS, 1996, 17 (06) :587-609

[6]

Beatson GT., 1896, LANCET, V148, P104, DOI DOI 10.1016/S0140-6736(01)72307-0

[7] MOLECULAR THEORY OF DRUG ACTION BASED ON INDUCED CONFORMATIONAL PERTURBATIONS OF RECEPTORS [J].

BELLEAU, B .

JOURNAL OF MEDICINAL CHEMISTRY, 1964, 7 (06) :776-&

[8] ROLE OF THE 2 ACTIVATING DOMAINS OF THE ESTROGEN-RECEPTOR IN THE CELL-TYPE AND PROMOTER-CONTEXT DEPENDENT AGONISTIC ACTIVITY OF THE ANTIESTROGEN 4-HYDROXYTAMOXIFEN [J].

BERRY, M ;

METZGER, D ;

CHAMBON, P .

EMBO JOURNAL, 1990, 9 (09) :2811-2818

[9] RALOXIFENE (LY139481 HCL) PREVENTS BONE LOSS AND REDUCES SERUM-CHOLESTEROL WITHOUT CAUSING UTERINE HYPERTROPHY IN OVARIECTOMIZED RATS [J].

BLACK, LJ ;

SATO, M ;

ROWLEY, ER ;

MAGEE, DE ;

BEKELE, A ;

WILLIAMS, DC ;

CULLINAN, GJ ;

BENDELE, R ;

KAUFFMAN, RF ;

BENSCH, WR ;

FROLIK, CA ;

TERMINE, JD ;

BRYANT, HU .

JOURNAL OF CLINICAL INVESTIGATION, 1994, 93 (01) :63-69

[10] Effects of raloxifene hydrochloride on the endometrium of postmenopausal women [J].

Boss, SM ;

Huster, WJ ;

Neild, JA ;

Glant, MD ;

Eisenhut, CC ;

Draper, MW .

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1997, 177 (06) :1458-1464

← 1 2 3 4 5 6 7 8 9 10 →